Biohaven Pharmaceutical (BHVN) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Biohaven Pharmaceutical (BHVN)

10.80

-0.60 (5.26%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

15 watching

Investor Insights

Jun 6, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Biohaven Pharmaceutical (BHVN-N) is demonstrating a strong commitment to advancing its drug pipeline across multiple therapeutic areas, including immunology, oncology, and neuroscience. Despite facing some setbacks in key clinical trials last year, which had high-profile failures, the company is making promising progress with several drugs currently in trial phases. These challenges highlight the volatile nature of pharmaceutical development, especially in innovative fields, but they also indicate that the company is pushing the boundaries of science. The mixed results from past trials create a cautious outlook among experts, as they assess the potential for future successes versus the risks of further setbacks. Overall, Biohaven's efforts underscore the dynamic environment of drug development where successes and failures can occur frequently.

Consensus

Cautious

Valuation

Fair Value

Similar

AMGN,AMGN

COMMENT

They have several drugs under trial in immunology, oncology and neuroscience. Are making good progress but last year they had some high-profile failures in key clinical trials.

DON'T BUY

Shares sold off last week after the FDA refused to review one of their drugs. Could be a buying opportunity, but the company is losing money.

BUY

The new Biohaven began trading last October after Pfizer bought the old one only for its migraine drug. The new Biohaven is far more speculative because there are many drugs in the pipeline in early stages. They held an R&D day this week and shares soared. He has faith in their new drugs.

BUY

A favourite of his. It plunged from $139 to $121 today. Whoa. Yesterday morning, they reported a solid quarter, and partnered with Pfizer to sell their big migraine pill overseas. But BHVN pre-announced strong results in early October so the good news is baked into the stock. The Pfizer news may be seen as a negative, because many investors expected BHVN to be a takeover candidate.

COMMENT

The caller bought at $33 It reports tomorrow afternoon. He likes it alot and uses their migraine money. Sell an amount equal to your cost based on $33/shares, then let it run. This way, you can't lose money.

BUY

Their super pill helped him control his migraine, so he's a fan of this stock.

BUY

Their drugs treated his migraine beautifully. The stock was downgraded yesterday, but he loves it.

COMMENT

They sell a super migraine pill he uses. It popped a year from around $25 to $100 in November, but since then it's pulled back to $72 today. It's a victim of the current rotation out of tech into cyclicals. That migraine pill is a steady seller and Biohaven also has a Parkinson's treatment in the pipeline as well as one for ALS. It could be worth buying into weakness.

BUY

Renown for their new migraine drug. Shares have tripled since April. He see more upside with their migraine pill (which he himself has taken and it's effective). Also consider their Alzheimer's drug which is being tested now.

Showing 1 to 9 of 9 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Biohaven Pharmaceutical (BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical stock symbol?

Biohaven Pharmaceutical is a American stock, trading under the symbol BHVN (previously BHVN-N on Stockchase) on the New York Stock Exchange (BHVN). It is usually referred to as NYSE:BHVN or BHVN

Is Biohaven Pharmaceutical a buy or a sell?

In the last year, there was no coverage of Biohaven Pharmaceutical published on Stockchase.

Is Biohaven Pharmaceutical a good investment or a top pick?

Biohaven Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Biohaven Pharmaceutical .

Why is Biohaven Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Biohaven Pharmaceutical worth watching?

0 stock analysts on Stockchase covered Biohaven Pharmaceutical in the last year. It is a trending stock that is worth watching.

What is Biohaven Pharmaceutical stock price?

On 2026-06-05, Biohaven Pharmaceutical (BHVN) stock closed at a price of $10.80.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Biohaven Pharmaceutical (BHVN)